Introduction: Olfactory dysfunction is commonly associated with Alzheimer’s disease (AD) and may be related to disorder of the central olfactory processing system. In this work, therefore, we examined the relationships between olfactory changes and the most affected cognitive domain or degree of brain atrophy in patients with AD and mild cognitive impairment (MCI). Methods: The subjects were 55 AD patients and 27 MCI patients. Smell identification tests were performed using Odor Stick Identification Test for Japanese -(OSIT-J). The severity and nature of cognitive dysfunctions were evaluated using the AD Assessment Scale-cognitive subscale, Japanese version (ADAS-Jcog). MRI with voxel-based specific regional analysis system for AD software was used for evaluation of brain atrophy. Results: -OSIT-J scores were significantly correlated with total -ADAS-Jcog scores, as well as with ADAS-Jcog subscale items of word recall task, orientation (memory domain) and ideational praxis. Smell identification deficit was proportional to the degree of atrophy of the medial temporal lobe. Conclusion: Smell identification deficit in AD/MCI is strongly associated with the memory domain of cognitive function and with atrophy of the medial temporal lobe.

Keywords:
Dementia, Alzheimer’s disease, Mild cognitive impairment , Olfactory deficit, Odor stick identification test for Japanese, Alzheimer’s disease assessment scale-cognitive subscale, Japanese version, Brain atrophy
1.
Duff K, McCaffrey RJ, Solomon GS; Duff K1. McCaffrey RJ, Solomon GS. The Pocket Smell Test: successfully discriminating probable Alzheimer’s dementia from vascular dementia and major depression.
J Neuropsychiatry
. 2002;14(2):197–201.
2.
Doty RL. Olfactory dysfunction in Parkinson disease.
Nat Rev Neurol
. 2012 May;8(6):329–39.
3.
Pardini M, Huey ED, Cavanagh AL, Grafman J. Olfactory function in corticobasal syndrome and frontotemporal dementia.
Arch Neurol
. 2009 Jan;66(1):92–6.
4.
Doty RL, Kamath V. The influences of age on olfaction: a review.
Front Psychol
. 2014 Feb;5:20.
5.
Lee EY, Eslinger PJ, Du G, Kong L, Lewis MM, Huang X. Olfactory-related cortical atrophy is associated with olfactory dysfunction in Parkinson’s disease.
Mov Disord
. 2014 Aug;29(9):1205–8.
6.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer’s disease.
Neurology
. 1984 Jul;34(7):939–44.
7.
Morris JC. Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia.
Arch Neurol
. 2012 Jun;69(6):700–8.
8.
Kobayashi M. The Odor Stick Identification Test for the Japanese (OSIT-J): clinical suitability for patients suffering from olfactory disturbance.
Chem Senses
. 2005 Jan;30 Suppl 1:i216–7.
9.
Homma A. [Assessment and treatment of patients with dementia of the Alzheimer type].
Nihon Ronen Igakkai Zasshi
. 1992 Apr;29(4):264–70.
10.
Verma N, Beretvas SN, Pascual B, Masdeu JC, Markey MK; Alzheimer’s Disease Neuroimaging Initiative. New scoring methodology improves the sensitivity of the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials.
Alzheimers Res Ther
. 2015 Nov;7(1):64.
11.
Matsuda H. Voxel-based morphometry of brain MRI in normal aging and Alzheimer’s disease.
Aging Dis
. 2013 Feb;4(1):29–37.
12.
Roalf DR, Moberg MJ, Turetsky BI, Brennan L, Kabadi S, Wolk DA, et al. A quantitative meta-analysis of olfactory dysfunction in mild cognitive impairment.
J Neurol Neurosurg Psychiatry
. 2017 Mar;88(3):226–32.
13.
Alves J, Petrosyan A, Magalhães R. Olfactory dysfunction in dementia.
World J Clin Cases
. 2014 Nov;2(11):661–7.
14.
Conti MZ, Vicini-Chilovi B, Riva M, Zanetti M, Liberini P, Padovani A, et al. Odor identification deficit predicts clinical -conversion from mild cognitive impairment to dementia due to Alzheimer’s disease.
Arch Clin Neuropsychol
. 2013 Aug;28(5):391–9.
15.
Yoo HS, Jeon S, Chung SJ, Yun M, Lee PH, Sohn YH, et al. Olfactory dysfunction in Alzheimer’s disease- and Lewy body-related cognitive impairment.
Alzheimers Dement
. 2018 Oct;14(10):1243–52.
16.
Kjelvik G, Saltvedt I, White LR, Stenumgård P, Sletvold O, Engedal K, et al. The brain structural and cognitive basis of odor identification deficits in mild cognitive impairment and Alzheimer’s disease.
BMC Neurol
. 2014 Aug;14(1):168.
17.
Zec RF, Landreth ES, Vicari SK, Belman J, Feldman E, Andrise A, et al. Alzheimer disease assessment scale: a subtest analysis.
Alzheimer Dis Assoc Disord
. 1992;6(3):164–81.
18.
Yoshii F, Kawaguchi C, Kohara S, Shimizu M, Onaka H, Ryo M, et al. Characteristic deterioration of ADAS-Jcog subscale scores and correlations with regional cerebral blood flow reductions in Alzheimer’s disease.
Neurol Sci
. 2018 May;39(5):909–18.
19.
Umeda-Kameyama Y, Ishii S, Kameyama M, Kondo K, Ochi A, Yamasoba T, et al. Heterogeneity of odorant identification impairment in patients with Alzheimer’s Disease.
Sci Rep
. 2017 Jul;7(1):4798.
20.
Vyhnalek M, Magerova H, Andel R, Nikolai T, Kadlecova A, Laczo J, et al. Olfactory identification in amnestic and non-amnestic mild cognitive impairment and its neuropsychological correlates.
J Neurol Sci
. 2015 Feb;349(1-2):179–84.
21.
Roberts RO, Christianson TJ, Kremers WK, Mielke MM, Machulda MM, Vassilaki M, et al. Association between olfactory dysfunction and amnestic mild cognitive impairment and Alzheimer disease dementia.
JAMA Neurol
. 2016 Jan;73(1):93–101.
22.
Kapur S, Craik FI, Jones C, Brown GM, Houle S, Tulving E. Functional role of the prefrontal cortex in retrieval of memories: a PET study.
Neuroreport
. 1995 Oct;6(14):1880–4.
23.
Nordin S, Murphy C. Impaired sensory and cognitive olfactory function in questionable Alzheimer’s disease.
Neuropsychology
. 1996;10(1):113–9.
24.
Devanand DP. Olfactory Identification Deficits, Cognitive Decline, and Dementia in Older Adults.
Am J Geriatr Psychiatry
. 2016 Dec;24(12):1151–7.
25.
Fujishiro H, Nakamura S, Kitazawa M, Sato K, Iseki E. Early detection of dementia with Lewy bodies in patients with amnestic mild cognitive impairment using 123I-MIBG cardiac scintigraphy.
J Neurol Sci
. 2012 Apr;315(1-2):115–9.
26.
Ferman TJ, Smith GE, Kantarci K, Boeve BF, Pankratz VS, Dickson DW, et al. Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies.
Neurology
. 2013 Dec;81(23):2032–8.
27.
Yoon JH, Kim M, Moon SY, Yong SW, Hong JM. Olfactory function and neuropsychological profile to differentiate dementia with Lewy bodies from Alzheimer’s disease in patients with mild cognitive impairment: A 5-year follow-up study.
J Neurol Sci
. 2015 Aug;355(1-2):174–9.
28.
Wang J, Eslinger PJ, Doty RL, Zimmerman EK, Grunfeld R, Sun X, et al. Olfactory deficit detected by fMRI in early Alzheimer’s disease.
Brain Res
. 2010 Oct;1357:184–94.
29.
Förster S, Vaitl A, Teipel SJ, Yakushev I, Mustafa M, la Fougère C, et al. Functional representation of olfactory impairment in early Alzheimer’s disease.
J Alzheimers Dis
. 2010;22(2):581–91.
30.
Devanand DP, Lentz C, Chunga RE, Ciarleglio A, Scodes JM, Andrews H, et al. Change in odor identification impairment is associated with improvement with cholinesterase inhibitor treatment in mild cognitive impairment.
J Alzheimers Dis
. 2017;60(4):1525–31.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.